{"entity":{"id":"herby","kind":"trial","name":"HERBY","aka":[],"tldr":"HERBY asked whether adding the anti-blood-vessel antibody bevacizumab to radiotherapy and temozolomide would help children with high-grade brain tumours; it did not delay the tumours returning, so the drug is not part of standard treatment for these children.","summary":"HERBY was an open-label randomised phase 2 trial in children and adolescents with newly diagnosed high-grade glioma outside the brainstem. After surgery, patients received radiotherapy with concurrent and adjuvant temozolomide, with or without bevacizumab.\n\nAdding bevacizumab did not improve event-free survival, the primary endpoint, as judged by central review, and did not improve overall survival. The trial did produce one of the best-characterised molecular cohorts of paediatric high-grade glioma; its biology sub-study showed that histone H3 and IDH mutation status, rather than histology, separated the outcomes, which fed into the WHO classification of these tumours.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT01390948","url":"https://clinicaltrials.gov/study/NCT01390948"}],"tags":["subtype-trials"],"related":[],"cancers":["paediatric-high-grade-glioma","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab","temozolomide"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jacques-grill"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01390948","phase":"2","setting":"Newly diagnosed non-brainstem high-grade glioma in children and adolescents aged 3 to 18: radiotherapy with temozolomide, with or without bevacizumab","sponsor":"Roche","result":"Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.","yearReported":2018,"enrolled":124,"outcomes":[{"endpoint":"Event-free survival (central radiology review)","primary":true,"unit":"months","arms":[{"name":"Bevacizumab + radiotherapy + temozolomide","n":62,"value":8.2},{"name":"Radiotherapy + temozolomide","n":59,"value":11.8}],"hr":1.44,"p":"0.13","source":"https://doi.org/10.1200/jco.2017.76.0611"},{"endpoint":"Overall survival","arms":[{"name":"Bevacizumab + radiotherapy + temozolomide","n":62,"note":"Medians not reported in the abstract"},{"name":"Radiotherapy + temozolomide","n":59}],"hr":1.23,"ci":[0.72,2.09],"source":"https://doi.org/10.1200/jco.2017.76.0611"},{"endpoint":"Serious adverse events","unit":"%","arms":[{"name":"Bevacizumab + radiotherapy + temozolomide","n":62,"value":58},{"name":"Radiotherapy + temozolomide","n":59,"value":48}],"source":"https://doi.org/10.1200/jco.2017.76.0611"}]},"route":"/trials/herby/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"paediatric-high-grade-glioma","kind":"cancer","name":"Paediatric high-grade glioma (excluding diffuse midline glioma)","route":"/cancers/paediatric-high-grade-glioma/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"person":[{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/"}]}}